title: Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy.
abstract: 58 patients with advanced bladder cancer were treated with MVEC chemotherapy (methotrexate, vinblastine, epirubicin and cisplatinum). 22 patients suffered from locally advanced disease (pT3-4 M0 N0), in 20 patients regional lymph node metastases were found (pT3-4 N1-3 M0). In 16 patients distant metastases were noted (pT1-4 N0-1 M1). In 89% transitional cell and in 11% squamous cell cancer or anaplastic carcinoma was seen. Complete response was noted in 45%, partial response in 23% and no response in 32%. Tissue polypeptide antigen (TPA) was registered before each course of chemotherapy and 3 months after the last application. The sensitivity for (pT3-4 N0 M0) tumors was 90.9%, for (pT3-4 N1-3 M0) 100% and for tumors with distant metastases 100% also, overall 96.6%. No statistically significant different values between each tumor group were found. In 85.7% a concordant reaction of TPA values and clinical status was notable. In conclusion, TPA has been proven as a valuable and a reliable marker for monitoring therapeutic efficacy of chemotherapy for advanced bladder cancer.
authors.affiliation: Department of Urology, Katharinenhospital, Stuttgart, FRG.
authors.forename: A
authors.initials: A
authors.lastname: Schmidt
authors.forename: P
authors.initials: P
authors.lastname: Bub
authors.forename: U
authors.initials: U
authors.lastname: Rüther
authors.forename: F
authors.initials: F
authors.lastname: Eisenberger
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010455:Peptides / Q000097:blood*; D012680:Sensitivity and Specificity; D019396:Tissue Polypeptide Antigen; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; D010455:Peptides; D019396:Tissue Polypeptide Antigen; D015251:Epirubicin; D014747:Vinblastine; D002945:Cisplatin; D008727:Methotrexate